{"schema_version":"secwatch.filing_event.v1","accession":"0001386570-25-000015","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.278608+00:00","generated_at":"2026-05-17T04:33:34.018119+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY","bullets":["Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.","CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.","Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.","Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001386570-25-000015","json":"https://secwatch.observer/filing/0001386570-25-000015.json","markdown":"https://secwatch.observer/filing/0001386570-25-000015.md","text":"https://secwatch.observer/filing/0001386570-25-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/0001386570-25-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/cdxc-20251006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:33:34.018119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}